Synaffix, ADC Therapeutics Announces Agreement
Complete the form below to unlock access to ALL audio articles.
AMS Synaffix BV has announced that it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody drug conjugate technologies. Under the terms of the agreement, ADC Therapeutics has been granted a single-target license for one of its preclinical programs and has also been granted an option to take a limited number of additional single-target licenses for potential future programs.
Floris van Delft, CSO at Synaffix said, “We are delighted that ADC Therapeutics has recognized the value of our proprietary antibody-drug conjugate technologies and has elected to incorporate Synaffix technology into one of its preclinical programs.”
“The experience of Synaffix and its partners has consistently confirmed that, in preclinical models, our proprietary GlycoConnect™ and HydraSpace™ technologies significantly improved both efficacy and safety as compared to other mainstream site-specific conjugation approaches.”
“We look forward to working closely with the ADC Therapeutics team to advance these promising therapeutics to the patients who need them.” Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis.